R. Tabata

Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?

Hiroyuki Takahashi, S. Egawa, H. Sasaki, 2016, Cancer Medicine.

[EXPRESSION OF PLAKIN FAMILY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT].

Hiroyuki Takahashi, S. Egawa, H. Yamada, 2017, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy

C. Ohyama, S. Hatakeyama, H. Yamamoto, 2023, Scientific Reports.

Does docetaxel prolong survival of patients with non‐metastatic castration‐resistant prostate cancer?

S. Egawa, Masayuki Tomita, Kagenori Ito, 2018, The Prostate.

Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study

C. Ohyama, Toshikazu Tanaka, S. Hatakeyama, 2023, International journal of urology : official journal of the Japanese Urological Association.

Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study

C. Ohyama, Toshikazu Tanaka, S. Hatakeyama, 2022, The Prostate.

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.

T. Habuchi, C. Ohyama, M. Saito*, 2023, Cancer medicine.

Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study

C. Ohyama, S. Hatakeyama, N. Fujita, 2023, Prostate international.